Loading clinical trials...
Loading clinical trials...
This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast follow...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Nextrast, Inc.
Collaborators
NCT06376695 · Abdominal Pain, GI Disorders, and more
NCT07069816 · GI Disorders
NCT04931420 · Metastatic Cancer, Foregut Carcinoid Tumor, and more
NCT05654909 · Pneumonia, Urinary Tract Infections, and more
Mayo Clinic
Rochester, Minnesota
University of Washington
Seattle, Washington
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions